Prostate cancer: Screening approaches

British Journal of Hospital Medicine

Volumn 66, Issue 11, 2005, Pages 623-626

  Donovan, J L ^a   Martin, R M ^a   Neal, D E ^b   Hamdy, F C ^c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; MALE; MASS SCREENING; METHODOLOGY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY AND SPECIFICITY;

EVIDENCE-BASED MEDICINE; HUMANS; MALE; MASS SCREENING; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SENSITIVITY AND SPECIFICITY;

EID: 33645498356     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2005.66.11.20023     Document Type: Conference Paper

References (21)

1. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293: 2095-101
2. Begg CB, Riedel ER, Bach PB et al (2002) Variations in morbidity after radical prostatectomy. N Engl J Med 346(15): 1138-44
3. Bill-Axelson A, Holmberg L, Ruutu M et al (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352(19): 1977-84
4. Crundwell MC, Cooke PW, Wallace DM (1999) Patients' tolerance of transrectal ultrasound-guided prostatic biopsy: an audit of 104 cases. BJU Int 83(7): 792-5
5. Donovan J, Mills N, Smith M et al (2002) Quality improvement report: improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. BMJ 325(7367): 766-70
6. Donovan JL, Hamdy FC, Neal DE et al (2003) Prostate testing for cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 7(l4): 1-42
7. Draisma G, Boer R, Otto SJ et al (2003) lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95(12): 868-78
8. Frankel S, Davey Smith G, Donovan J, Neal D (2003) Screening for prostate cancer. Lancet 361(9363): 1122-8
9. Gronberg H (2003) Prostate cancer epidemiology. Lancet 361(9360): 859-64
10. Jani AB, Hellman S (2003) Early prostate cancer: clinical decision-making. Lancet 361(9362): 1045-53
11. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ (2002) Natural experiment examining impact of aggressive-screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325(7367): 740-6
12. McGregor M, Hanley JA, Boivin JF, McLean RG (1998) Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 159(11): 1368-72
13. Oliver SE, Gunnell D, Donovan JL (2000) Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 355(9217): 1788-9
14. Ostrander EA, Markianos K, Stanford JL (2004) Finding prostate cancer susceptibility genes. Annu Rev Genomics Hum Genet 5(1): 151-75
15. Rosen MA (1995) Impact of prostate-specific antigen screening on the natural history of prostate cancer. Urology 46(6): 757-68
16. Steineck G, Helgesen F, Adolfsson J et al (2002) Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347: 790-6
17. Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level <=4.0 ng per milliliter. N Engl J Med 350(22): 2239-46
18. Thompson IM, Ankerst DP, Chi C et al (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA: 294(1): 66-70
19. Toms JR, ed. (2004) CancerStats Monograph. Cancer Research UK, London
20. Whitmore WF Jr (1994) Localised prostatic cancer: management and detection issues. Lancet 343(8908): 1263-7
21. Wilt TJ, Brawer MK (1994) The prostate cancer intervention versus observation trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 152: 1910-14